Clinicopathological characteristics associated with the prognosis of recurrent gonadotroph tumors

in Endocrine-Related Cancer
Authors:
Chrysi Kaparounaki Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, “Groupement Hospitalier Est” Hospices Civils de Lyon, Bron, France
Third Department of Internal Medicine, 417 Army Equity Fund Hospital (NIMTS), Athens, Greece

Search for other papers by Chrysi Kaparounaki in
Current site
Google Scholar
PubMed Close
,
Alexandre Vasiljevic Pathology Department, Reference Center for Rare Pituitary Diseases HYPO, “Groupement Hospitalier Est” Hospices Civils de Lyon, Bron, France
Inserm U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Cancer Research Center of Lyon, Lyon, France

Search for other papers by Alexandre Vasiljevic in
Current site
Google Scholar
PubMed Close
,
Emmanuel Jouanneau Inserm U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Cancer Research Center of Lyon, Lyon, France
Neurosurgery Department, Reference Center for Rare Pituitary Diseases HYPO, “Groupement Hospitalier Est” Hospices Civils de Lyon, Bron, France

Search for other papers by Emmanuel Jouanneau in
Current site
Google Scholar
PubMed Close
,
Camille Sergeant Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, “Groupement Hospitalier Est” Hospices Civils de Lyon, Bron, France

Search for other papers by Camille Sergeant in
Current site
Google Scholar
PubMed Close
,
Gérald Raverot Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, “Groupement Hospitalier Est” Hospices Civils de Lyon, Bron, France
Inserm U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Cancer Research Center of Lyon, Lyon, France

Search for other papers by Gérald Raverot in
Current site
Google Scholar
PubMed Close
https://orcid.org/0000-0002-9517-338X
, and
Mirela-Diana Ilie Inserm U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Cancer Research Center of Lyon, Lyon, France
Endocrinology Department, “C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania

Search for other papers by Mirela-Diana Ilie in
Current site
Google Scholar
PubMed Close
https://orcid.org/0000-0001-7248-7258

Correspondence should be addressed to G Raverot: gerald.raverot@chu-lyon.fr or to M-D Ilie: mireladiana.ilie@gmail.com

This paper is part of a special collection highlighting the work of emerging leaders in the endocrine cancer field.

DOI:
https://doi.org/10.1530/ERC-24-0186
Volume/Issue:
Volume 32: Issue 6
Article Type:
Research Article
Article ID:
e240186
Online Publication Date:
13 May 2025
Copyright:
© the author(s) 2025
Restricted access
Rent on DeepDyve

Sign up for journal news

Although gonadotroph tumor regrowth is frequent after pituitary surgery, the systematic use of adjuvant radiotherapy is limited by its long-term complications. In this context, it is important to predict which tumors are most likely to regrow after surgery, and especially, which tumors are most likely to regrow rapidly. Clinicopathological characteristics associated with the prognosis of radiotherapy-naïve, recurrent pituitary tumors are currently unknown. In this longitudinal, observational, retrospective, monocentric cohort study, we analyzed the clinicopathological characteristics associated with the prognosis of recurrent, radiotherapy-naïve gonadotroph tumors, specifically with the progression-free survival after a second pituitary surgery. We found that the Ki67 index of radiotherapy-naïve, recurrent gonadotroph tumors was the only parameter statistically associated with the progression-free survival after a second pituitary surgery, P = 0.02. Specifically, radiotherapy-naïve gonadotroph tumors with a positive Ki67 index had shorter progression-free survival after the second surgery (median 31 months) compared to radiotherapy-naïve gonadotroph tumors with a negative Ki67 index (median 75 months). Thus, our study pinpoints that the Ki67 index could be used to guide the management strategy for recurrent gonadotroph tumors that are still radiotherapy-naïve by the time of the second pituitary surgery.

Endocrine-Related Cancer is committed to supporting researchers in demonstrating the impact of their articles published in the journal.

The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.

More information is on the Reasons to publish page.

Sept 2018 onwards Past Year Past 30 Days
Full Text Views 26 26 15
PDF Downloads 40 40 22

 

  • Collapse
  • Expand
Print ISSN:
1351-0088
Online ISSN:
1479-6821
Copyright:
© the author(s) 2025
Article ID:
e240186
Received Date:
29 Jul 2024
Rev-recd:
24 Apr 2025
Accepted Date:
30 Apr 2025
Print Publication Date:
01 Jun 2025
Online Publication Date:
13 May 2025
Keywords:
pituitary adenoma; pituitary tumor; gonadotroph adenoma; recurrence; progression-free survival

  • Dubois S , Guyétant S , Menei P , et al. 2007 Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. Eur J Endocrinol 157 141–147. (https://doi.org/10.1530/EJE-07-0099)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Esposito D , Olsson DS , Ragnarsson O , et al. 2019 Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management. Pituitary 22 422–434. (https://doi.org/10.1007/s11102-019-00960-0)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Hamblin R , Vardon A , Akpalu J , et al. 2022 Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma: a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillance. Lancet Diabetes Endocrinol 10 581–588. (https://doi.org/10.1016/S2213-8587(22)00160-7)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Hussein Z , Slack RW , Baldeweg SE , et al. 2024 Machine learning analysis of post-operative tumour progression in non-functioning pituitary neuroendocrine tumours: a pilot study. Cancers 16 1199. (https://doi.org/10.3390/cancers16061199)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Ilie MD & Raverot G 2020 Treatment options for gonadotroph tumors: current state and perspectives. J Clin Endocrinol Metab 105 e3507–e3518. (https://doi.org/10.1210/clinem/dgaa497)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Ilie MD , Vasiljevic A , Louvet C , et al. 2020 Gonadotroph tumors show subtype differences that might have implications for therapy. Cancers 12 1012. (https://doi.org/10.3390/cancers12041012)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Melmed S 2020 Pituitary-tumor endocrinopathies. N Engl J Med 382 937–950. (https://doi.org/10.1056/NEJMra1810772)

  • Melmed S , Kaiser UB , Lopes MB , et al. 2022 Clinical biology of the pituitary adenoma. Endocr Rev 43 1003–1037. (https://doi.org/10.1210/endrev/bnac010)

  • Micko ASG , Wöhrer A , Wolfsberger S , et al. 2015 Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg 122 803–811. (https://doi.org/10.3171/2014.12.JNS141083)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Ntali G & Karavitaki N 2015 Efficacy and complications of pituitary irradiation. Endocrinol Metab Clin N Am 44 117–126. (https://doi.org/10.1016/j.ecl.2014.10.009)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • O’Sullivan EP , Woods C , Glynn N , et al. 2009 The natural history of surgically treated but radiotherapy-naïve nonfunctioning pituitary adenomas. Clin Endocrinol 71 709–714. (https://doi.org/10.1111/j.1365-2265.2009.03583.x)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Park P , Chandler WF , Barkan AL , et al. 2004 The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery 55 100–107. (https://doi.org/10.1227/01.NEU.0000126885.71242.D7)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Raverot G , Dantony E , Beauvy J , et al. 2017 Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification. J Clin Endocrinol Metab 102 3368–3374. (https://doi.org/10.1210/jc.2017-00773)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Reddy R , Cudlip S , Byrne JV , et al. 2011 Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma? Eur J Endocrinol 165 739–744. (https://doi.org/10.1530/EJE-11-0566)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Tampourlou M , Ntali G , Ahmed S , et al. 2017 Outcome of nonfunctioning pituitary adenomas that regrow after primary treatment: a study from two large UK centers. J Clin Endocrinol Metab 102 1889–1897. (https://doi.org/10.1210/jc.2016-4061)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Trouillas J , Roy P , Sturm N , et al. 2013 A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126 123–135. (https://doi.org/10.1007/s00401-013-1084-y)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Villa C , Baussart B , Assié G , et al. 2023 The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal. Endocr Relat Cancer 30 e230021. (https://doi.org/10.1530/ERC-23-0021)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Woollons AC , Hunn MK , Rajapakse YR , et al. 2000 Non-functioning pituitary adenomas: indications for postoperative radiotherapy. Clin Endocrinol 53 713–717. (https://doi.org/10.1046/j.1365-2265.2000.01153.x)

    • PubMed
    • Search Google Scholar
    • Export Citation